Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMIU0VP)

Drug Name

SNX-5422 Drug Info

Synonyms

908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 1/2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 1	[1]
Neuroendocrine cancer	2B72.1	Phase 1	[1]

Cross-matching ID

PubChem CID: 44195571
CAS Number: CAS 908115-27-5
TTD Drug ID: DMIU0VP

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[2] , [3]
Heat shock protein 90 beta (HSP90B)	TTH5YN2	HS90B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Heat shock protein 90 alpha (HSP90A)	DTT	HSP90AA1	9.604	9.034	9.856	9.2

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Haematological malignancy

ICD Disease Classification

2B33.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Heat shock protein 90 alpha (HSP90A)	DTT	HSP90AA1	3.96E-01	0.18	0.48

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
3	Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008 Aug;8(4):370-4.